NEU 2.81% $18.65 neuren pharmaceuticals limited

Video on trofinetide up on web site, page-6

  1. 915 Posts.
    lightbulb Created with Sketch. 254
    Great video Hardoak .  It highlights the significance of what this drug can do especially in targeting those 4 key concepts of brain function/activity.  I am continually excited about restoring synaptic function and reducing neuro-inflammation.  I have stated it before but this drug could be in the embryonic phases of being a new frontier in the treatment of a lot of CNS conditions .  A lot of neurological diseases - have abnormal activity in at least 1 of the 4 aspects that Trof targets.  The big question is - how efficacious is it???

    It sort of reminds me of the invention of monoclonal antibodies in the treatment of auto-immune disorders, only this is on a larger scale and in diseases/conditions that have been notoriously difficult to treat (or unable to treat).  I.e. - exciting new technology that will re-write the therapeutic guidelines on how we treat disease.

    Im really interested to see the MS models , epilepsy, neuropathic pain, Parkinsons and Alzheimers.

    Be also interested to see given it has anxiolytic effects - if it has a role  in the treatment in depression, schizophrenia, bipolar and mood disorders down the track.  Again the effect on restoring synaptic function & neurotransmission would in theory make it suitable as well for those conditions.

    Most people have a brain so the target market could be enourmous!
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.